1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL GLAUCOMA SURGERY MARKET, BY TARGET
5.1 TRABECULAR MESHWORK
5.2 SUPRACHOROIDAL SPACE
5.3 OTHERS
6. GLOBAL GLAUCOMA SURGERY MARKET, BY TYPE OF SURGERY
6.1 ANGLE CLOSURE GLAUCOMA SURGERY
6.2 AQUEOUS SHUNT SURGERY
6.3 LASER SURGERY
6.4 OTHER
7. GLOBAL GLAUCOMA SURGERY MARKET, BY END USER
7.1 HOSPITAL
7.2 AMBULATORY SURGERY CENTERS
7.3 OTHER
8. GLOBAL GLAUCOMA SURGERY MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 WESTERN EUROPE
8.3.1.1 GERMANY
8.3.1.2 FRANCE
8.3.1.3 ITALY
8.3.1.3 SPAIN
8.3.1.5 UK
8.3.1.6 REST OF WESTERN EUROPE
8.3.2 EASTERN EUROPE
8.4 ASIA
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 REPUBLIC OF KOREA
8.5 REST OF ASIA-PACIFIC
8.6 MIDDLE EAST & AFRICA
8.6.1 UNITED ARAB EMIRATES
8.6.2 SAUDI ARABIA
8.6.3 OMAN
8.6.4 KUWAIT
8.6.5 QATAR
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 ALLERGAN
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 TEVA PHARMACEUTICALS
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 NOVARTIS AG
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 PFIZER
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 ELLEX MEDICAL LASERS.
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS